{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:39:05Z","timestamp":1761748745424,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.acvd.2021.10.005","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T11:59:20Z","timestamp":1637323160000},"page":"805-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Percutaneous mitral valve repair in severe secondary mitral regurgitation: Analysis of index hospitalization and economic evaluation based on the MITRA-FR trial"],"prefix":"10.1016","volume":"114","author":[{"given":"Aude","family":"Capelle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Francois","family":"Obadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Iung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Messika-Zeitoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alec","family":"Vahanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Leurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-No\u00ebl","family":"Trochu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Armoiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2021.10.005_bib0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.acvd.2013.03.059","article-title":"Initial French experience of percutaneous mitral valve repair with the MitraClip: a multicentre national registry","volume":"106","author":"Armoiry","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.10.005_bib0120","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.4244\/EIJV10I11A232","article-title":"The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation","volume":"10","author":"Obadia","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.acvd.2021.10.005_bib0125","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.005_bib0130","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/ejhf.1616","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years","volume":"21","author":"Iung","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2021.10.005_bib0135","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.005_bib0140","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","article-title":"Guidelines on the management of valvular heart disease (version 2012)","volume":"33","author":"Vahanian","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.005_bib0145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.acvd.2013.01.006","article-title":"Cost of transcatheter aortic valve implantation and factors associated with higher hospital stay cost in patients of the FRANCE (FRench Aortic National CoreValve and Edwards) registry","volume":"106","author":"Chevreul","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.10.005_bib0150","unstructured":"Aide au Codage. \u00c9chographie-doppler transthoracique du coeur et des vaisseaux intrathoraciques (DZQM006). Available at: https:\/\/www.aideaucodage.fr\/ccam-dzqm006.[accessed date: 22 December 2020]."},{"key":"10.1016\/j.acvd.2021.10.005_bib0155","unstructured":"L\u00e9gifrance. D\u00e9cision du 13 octobre 2016 de l\u2019Union nationale des caisses d\u2019assurance maladie relative \u00e0 la liste des actes et prestations pris en charge par l\u2019assurance maladie; 2016. Available at: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000033385793.[accessed date: 22 October 2021]."},{"key":"10.1016\/j.acvd.2021.10.005_bib0160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00392-015-0918-0","article-title":"Transcatheter mitral valve repair with the MitraClip\u00ae can be performed without general anesthesia and without conscious sedation","volume":"105","author":"Ledwoch","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.acvd.2021.10.005_bib0165","unstructured":"Stone GW. COAPT: A randomized trial of transcatheter mitral valve leaflet approximation in patients with heart failure and secondary mitral regurgitation; 2018. Available at: https:\/\/www.tctmd.com\/slide\/coapt-randomized-trial-transcatheter-mitral-valve-leaflet-approximation-patients-heart.[accessed date: 22 October 2021]."},{"key":"10.1016\/j.acvd.2021.10.005_bib0170","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jcin.2019.02.039","article-title":"Institutional experience with transcatheter mitral valve repair and clinical outcomes: insights from the TVT registry","volume":"12","author":"Chhatriwalla","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2021.10.005_bib0175","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1053\/j.jvca.2014.05.005","article-title":"Do patients undergoing MitraClip implantation require routine ICU admission?","volume":"28","author":"Di Prima","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.acvd.2021.10.005_bib0180","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/eurheartj\/ehv627","article-title":"One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry","volume":"37","author":"Puls","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.005_bib0185","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jacc.2013.02.094","article-title":"Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe","volume":"62","author":"Maisano","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.005_bib0190","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.119.043275","article-title":"Cost-effectiveness of transcatheter mitral valve repair versus medical therapy in patients with heart failure and secondary mitral regurgitation: results from the COAPT trial","volume":"140","author":"Baron","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.005_bib0195","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.acvd.2019.07.002","article-title":"Is the MitraClip\u00ae procedure profitable in a high-volume French hospital?","volume":"112","author":"Mahdjoub","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.10.005_bib0200","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.acvd.2014.09.008","article-title":"Economic burden of functional and organic mitral valve regurgitation","volume":"108","author":"Trochu","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.10.005_bib0205","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jcin.2020.09.057","article-title":"Percutaneous treatment of mitral regurgitation with the PASCAL device: a full grasp of the pathology?","volume":"13","author":"Leurent","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2021.10.005_bib0210","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1161\/CIRCULATIONAHA.120.049743","article-title":"Characteristics and outcome of COAPT-eligible patients in the MITRA-FR trial","volume":"142","author":"Iung","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.005_bib0215","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcmg.2020.07.021","article-title":"Impact of mitral regurgitation severity and left ventricular remodeling on outcome after MitraClip implantation: results from the Mitra-FR trial","volume":"14","author":"Messika-Zeitoun","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.acvd.2021.10.005_bib0220","doi-asserted-by":"crossref","first-page":"e0241361","DOI":"10.1371\/journal.pone.0241361","article-title":"Conflicting findings between the Mitra-Fr and the Coapt trials: implications regarding the cost-effectiveness of percutaneous repair for heart failure patients with severe secondary mitral regurgitation","volume":"15","author":"Armoiry","year":"2020","journal-title":"PLoS One"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213621001741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213621001741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:48:03Z","timestamp":1761745683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213621001741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1875213621001741"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2021.10.005","relation":{},"ISSN":["1875-2136"],"issn-type":[{"type":"print","value":"1875-2136"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Percutaneous mitral valve repair in severe secondary mitral regurgitation: Analysis of index hospitalization and economic evaluation based on the MITRA-FR trial","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2021.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}